ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
Targeting diabetes with flavonoids from Indonesian medicinal plants: a review on mechanisms and drug discovery.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rich biodiversity of Indonesia provides a wide variety of plants rich in flavonoids, which show promising potential as antidiabetic agents. Flavonoids are polyphenolic compounds recognized for their broad biological activities, such as antioxidant, anti-inflammatory, and antidiabetic effects. Traditional Indonesian medicinal plants such as Syzygium cumini, Moringa oleifera, and Curcuma longa are currently being studied for their flavonoid content and potential in diabetes treatment. Studies suggest that flavonoids can influence crucial pathways in diabetes management, including enhancing insulin sensitivity, boosting insulin production, and safeguarding pancreatic β cells against damage caused by oxidative stress. For example, quercetin and kaempferol, flavonoids in many Indonesian plants, have demonstrated potential for managing glucose metabolism and lowering high blood sugar levels. Additionally, these substances have been shown to inhibit enzymes such as α-glucosidase and α-amylase, which are involved in the breakdown of carbohydrates, thus aiding in the regulation of blood sugar levels after meals. The antioxidant qualities of flavonoids play a crucial role in fighting oxidative stress and are a significant contributor to the development of diabetes and related complications. Flavonoids help neutralize free radicals and enhance the body's antioxidant protection, reducing oxidative harm and promoting metabolic wellness. Additionally, their anti-inflammatory properties aid in reducing the chronic inflammation linked to insulin resistance and β-cell dysfunction. Formulation advancements, such as nanocarrier technology, have been explored to boost the effectiveness of flavonoid-based therapies. Due to its vast plant diversity, Indonesia offers a potential reservoir for new antidiabetic drugs, meriting additional research and development with the aim of this review providing new knowledge on the potential of flavonoids that can play a role in the treatment of diabetes.
Indexed as
Identifiers
40202673What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.